Compare Expensify Inc (EXFY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Recursion Pharmaceuticals Inc — how do they compare? Expensify Inc trades at $2.27 (market cap $209.73M), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 8.6× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| EXFY | RXRX | |
|---|---|---|
Market Cap | $209.73M | $1.81B |
Sector | Technology | Health |
52-Week High | $2.69 | $6.79 |
52-Week Low | $0.75 | $2.84 |
Enterprise Value | $149.35M | $1.33B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
